Lidocaine/Prilocaine Optimal for Deeper Dermal Laser Procedures

This article originally appeared here.
Share this content:
Lidocaine/Prilocaine Optimal for Deeper Dermal Laser Procedures
Lidocaine/Prilocaine Optimal for Deeper Dermal Laser Procedures

THURSDAY, July 14, 2016 (HealthDay News) -- For patients undergoing deeper dermal laser treatments of acne keloidalis nuchae (AKN) and tattoos, lidocaine/prilocaine cream is better for reducing pain than lidocaine/tetracaine cream, according to a study published online July 5 in the British Journal of Dermatology.

Karin Greveling, M.D., from the Erasmus University Medical Center in Rotterdam, Netherlands, and colleagues compared the efficacy of lidocaine/tetracaine cream and lidocaine/prilocaine cream in reducing pain during deeper dermal laser treatments of AKN and tattoos. Two randomized trials were conducted involving 15 patients with AKN (Study A) and 15 with black tattoos (Study B).

The researchers found that visual analogue scale (VAS) scores were lower for lidocaine/prilocaine cream in both studies, with a mean VAS difference of 1.9 and 0.6 in Study A and B, respectively. Adequate pain relief was achieved in 13 percent with lidocaine/tetracaine, compared to 73 percent with lidocaine/prilocaine in Study A (P = 0.004); the corresponding proportions in Study B were 53 and 80 percent (P = 0.289). In Study A and Study B, 47 and 73 percent of participants, respectively, were willing to pay an additional 25 euros. There were no serious adverse events reported.

"Lidocaine/prilocaine cream under plastic occlusion is the preferred topical anesthetic during painful laser procedures targeting dermal chromophores," the authors write.

Pliaglis was donated by the manufacturer, Galderma.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »